SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Jenburkt Pharma - Quaterly Results

28 May 2024 Evaluate
The company witnessed a 10.35% growth in the revenue at Rs. 388.42 millions for the quarter ended March 2024 as compared to Rs. 351.99 millions during the year-ago period.The Company has registered profit of Rs. 78.83  millions for the quarter ended March 2024, a growth of 24.06%  over Rs. 63.54 millions millions achieved in the corresponding quarter of last year.Operating profit for the quarter ended March 2024 rose to 110.42 millions as compared to 87.54 millions of corresponding quarter ended March 2023.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202403 202303 % Var 202403 202303 % Var 202403 202303 % Var
Sales 388.42 351.99 10.35 1419.66 1367.49 3.82 1419.66 1367.49 3.82
Other Income 11.89 12.56 -5.33 46.67 51.23 -8.90 46.67 51.23 -8.90
PBIDT 110.42 87.54 26.14 377.85 354.90 6.47 377.85 354.90 6.47
Interest 0.58 0.84 -30.95 2.71 3.67 -26.16 2.71 3.67 -26.16
PBDT 109.84 86.70 26.69 375.14 351.23 6.81 375.14 351.23 6.81
Depreciation 6.18 5.94 4.04 23.40 22.59 3.59 23.40 22.59 3.59
PBT 103.66 80.76 28.36 351.74 328.64 7.03 351.74 328.64 7.03
TAX 24.83 17.22 44.19 91.98 82.58 11.38 91.98 82.58 11.38
Deferred Tax -1.68 1.62 -203.70 -5.21 -2.25 131.56 -5.21 -2.25 131.56
PAT 78.83 63.54 24.06 259.76 246.06 5.57 259.76 246.06 5.57
Equity 44.13 44.13 0.00 44.13 44.13 0.00 44.13 44.13 0.00
PBIDTM(%) 28.43 24.87 14.31 26.62 25.95 2.55 26.62 25.95 2.55

Jenburkt Pharma Share Price

1061.95 11.55 (1.10%)
21-Apr-2026 10:30 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1670.05
Dr. Reddys Lab 1223.90
Cipla 1230.70
Zydus Lifesciences 929.55
Lupin 2325.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×